▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #516 by analyst upside · 2026-09-04
TELA
TELA Bio, Inc.
Healthcare · Market Cap $35M · P/E 0x
ANALYST PRICE TARGET
+168.9%
implied upside to consensus target
Current Price $0.78
Consensus Target $2.1
Bull Target $3.0
Bear Target $1.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
1
Sell
0
52-Week Low $0.5
52-Week High $1.73
YTD Return +0.0%
FUNDAMENTALS
Market Cap $35M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $80M
Profit Margin -51.5%
52-WEEK RANGE
52-Week Low $0.5
52-Week High $1.73
Current Price $0.78
Bear Target $1.0
Bull Target $3.0
● Now $0.78 ● Target $2.1
TRADING DATA
Avg Volume 160K
YTD Return +0.0%
Analyst Count 5
Consensus Buy
Upside to Target +168.9%
Last Updated 2026-09-04

ANALYST SUMMARY

TELA Bio, Inc. (TELA) is currently trading at $0.78 with a Wall Street consensus price target of $2.1, implying potential upside of 168.9% over the next 12 months. 5 analysts currently cover TELA, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $3.0, while the most cautious has a target of $1.0.

TELA operates in the Healthcare sector with a market capitalisation of $35M. The stock is up 0.0% year-to-date and is currently trading near the lower end of its 52-week range of $0.5 – $1.73.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ELOX +168.9%
Eloxx Pharmaceuticals, Inc.
$52M · P/E 3.9x · Buy
ATNM +233.3%
Actinium Pharmaceuticals, Inc.
$33M · P/E 3.0x · Buy
DXR +94.7%
Daxor Corporation
$60M · P/E 6.1x · Strong Buy
SPRO +230.6%
Spero Therapeutics, Inc.
$70M · P/E 8.6x · Hold
BSEM +88.7%
BioStem Technologies, Inc.
$66M · P/E 4.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for TELA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-27 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-03-25 14% win rate (7 calls)
Lake Street - Reiterated
Buy → Buy 2026-03-25 27% win rate (11 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-03-25 Building track record
Lake Street - Reiterated
Buy → Buy 2025-12-01 27% win rate (11 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2025-11-18 Building track record
Piper Sandler reit
Neutral → Neutral 2025-11-14 14% win rate (7 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2025-11-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →